State Street Corp Selecta Biosciences Inc Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.62 - $0.85 $71,307 - $97,760	-115,012 Reduced 5.22%	2,086,840 $1.75 Million
Q4 2023 Feb 14, 2024	BUY	$0.67 - $1.35 $112,953 - $227,593	168,588 Added 8.29%	2,201,852 $1.52 Million
Q3 2023 Nov 14, 2023	BUY	$1.02 - $1.23 $69,414 - $83,705	68,053 Added 3.46%	2,033,264 $2.16 Million
Q2 2023 Aug 14, 2023	BUY	$1.04 - $1.4 $1.61 Million - $2.16 Million	1,543,513 Added 366.02%	1,965,211 $2.2 Million
Q4 2022 Feb 14, 2023	SELL	$0.96 - $1.6 $2,400 - $4,000	-2,500 Reduced 0.59%	421,698 $476,000
Q3 2022 Nov 15, 2022	BUY	$1.33 - $2.6 $51,072 - $99,840	38,400 Added 9.95%	424,198 $696,000
Q2 2022 Aug 15, 2022	SELL	$0.67 - $1.4 $941,475 - $1.97 Million	-1,405,187 Reduced 78.46%	385,798 $505,000
Q1 2022 May 16, 2022	BUY	$1.23 - $3.31 $99,214 - $266,991	80,662 Added 4.72%	1,790,985 $2.2 Million
Q4 2021 Feb 14, 2022	SELL	$2.89 - $4.43 $7.86 Million - $12 Million	-2,719,665 Reduced 61.39%	1,710,323 $5.58 Million
Q3 2021 Nov 15, 2021	BUY	$3.36 - $4.62 $10.1 Million - $13.9 Million	3,017,394 Added 213.61%	4,429,988 $18.4 Million
Q2 2021 Aug 16, 2021	BUY	$2.82 - $5.01 $597,371 - $1.06 Million	211,834 Added 17.64%	1,412,594 $5.91 Million
Q1 2021 May 17, 2021	BUY	$2.92 - $5.07 $197,675 - $343,223	67,697 Added 5.97%	1,200,760 $5.43 Million
Q4 2020 Feb 16, 2021	SELL	$1.64 - $3.42 $84,446 - $176,102	-51,492 Reduced 4.35%	1,133,063 $3.43 Million
Q3 2020 Nov 10, 2020	BUY	$2.18 - $2.84 $138,046 - $179,840	63,324 Added 5.65%	1,184,555 $2.94 Million
Q2 2020 Aug 14, 2020	BUY	$1.83 - $4.06 $2.05 Million - $4.55 Million	1,121,231 New	1,121,231 $3.18 Million

Others Institutions Holding SELB

# of Institutions

Shares Held

4.67M

Call Options Held

Put Options Held

View Full List

About SELECTA BIOSCIENCES INC

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

More about SELB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account